Get the Stockscreener App
15.44
0.13%
0.02
Adaptive Biotechnologies Corp stock is traded at $15.44, with a volume of 2.12M.
It is up +0.13% in the last 24 hours and up +6.48% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$15.42
Open:
$15.38
24h Volume:
2.12M
Relative Volume:
0.94
Market Cap:
$2.36B
Revenue:
$205.22M
Net Income/Loss:
$-121.24M
P/E Ratio:
-18.97
EPS:
-0.8141
Net Cash Flow:
$-82.81M
1W Performance:
+4.68%
1M Performance:
+6.48%
6M Performance:
+48.32%
1Y Performance:
+150.65%
1-Day Range:
$15.11
$15.53
1-Week Range:
$14.58
$16.26
52-Week Range:
$5.805
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.44 | 2.35B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - Yahoo Finance
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biot - GuruFocus
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock - Investing.com
Adaptive Biotechnologies Exec Sells Over $670K in Company Stock - TradingView
Officer Robins Sells 37,212 ($672.5K) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share SaleHas The Bull Case Changed? - simplywall.st
Will Adaptive Biotechnologies Corporation stock beat EPS estimatesDollar Strength & AI Enhanced Trading Alerts - Newser
Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Will Adaptive Biotechnologies Corporation (1HM) stock draw ESG focused funds2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Will Adaptive Biotechnologies Corporation (1HM) stock sustain uptrend momentum2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback - Yahoo Finance
Ready to Jump After Recent Trade: Adaptive Biotechnologies Corp (ADPT) - setenews.com
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $2,367,462.12 in Stock - MarketBeat
ADPT FinancialsIncome Statement - Quiver Quantitative
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock - Investing.com
Adaptive Biotechnologies CFO Kyle Piskel Sells Over 162K Shares - TradingView
CFO Piskel Sells 162,820 ($3.2M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies (ADPT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ameritas Investment Partners Inc. Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - Defense World
Chad Robins Sells 160,734 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock - Investing.com
Adaptive Biotechnologies CEO Sells Shares Worth Over $3 Million - TradingView
Chmn Robins Sells 160,734 ($3.1M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Chmn Robins Files To Sell 124,998 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
CFO Piskel Files To Sell 162,820 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Geode Capital Management LLC Has $37.46 Million Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Street Watch: Why Adaptive Biotechnologies Corporation stock remains undervaluedGlobal Markets & Weekly High Return Opportunities - BỘ NỘI VỤ
Its Stock Has Paid Off Big Time For Adaptive Biotechnologies Corp - Setenews
Sharon Benzeno Sells 308,477 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock - MarketBeat
Adaptive Biotechnologies’ Benzeno sells $10.1m in shares By Investing.com - Investing.com India
Adaptive Biotechnologies’ Benzeno sells $10.1m in shares - Investing.com
Adaptive Biotechnologies CCO reports major option exercises, sales - Stock Titan
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):